Form 4: Shattuck Labs CEO Acquires Shares and Warrants

Shattuck Labs CEO Taylor Schreiber acquired 25,610 shares of common stock and accompanying warrants in a private placement.

Summary

• Taylor Schreiber, CEO of Shattuck Labs, Inc. (STTK), acquired 25,610 shares of common stock and warrants to purchase an additional 25,610 shares.
• The acquisition occurred on May 12, 2026, as part of a private placement that closed on August 25, 2025.
• The combined price per share and accompanying warrant was $0.8677.
• Schreiber's beneficial ownership of common stock is now 2,610,750 shares, held indirectly through Houghton Capital Holdings, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports an insider transaction without providing new financial or operational updates. While insider buying can be positive, the details are limited to the transaction itself.

Positives

• Insider buying by the CEO can signal confidence in the company's future prospects.
• Acquisition of both stock and warrants provides potential for future upside if the stock price increases.

Negatives

• The filing does not provide details on the financial performance or strategic updates of the company, focusing solely on a transaction by an insider.
• The purchase price of $0.8677 per share and warrant is relatively low, which could indicate a depressed stock price at the time of the transaction.

Risks

• The warrants are exercisable only after specific clinical trial data (single ascending dose and multiple ascending dose portions of SL-325, receptor occupancy, safety data) and the design of Phase 2 trials are publicly announced.
• The value of the warrants is contingent on the successful progression of Shattuck Labs' clinical trials and subsequent public announcements.

Future Outlook

The future outlook for the acquired warrants is tied to the public announcement of clinical trial data for SL-325 and the design of Phase 2 trials. The exact timing and nature of this announcement are not specified.

Industry Context

StockSavvy.ai notes that insider transactions, particularly by C-suite executives, are closely watched by the market as they can provide insights into management's perception of the company's value and future prospects. This transaction by the CEO of Shattuck Labs, a biopharmaceutical company, occurs within an industry heavily influenced by clinical trial outcomes and regulatory approvals.

Related Party Transactions

• Taylor Schreiber, CEO and Director of Shattuck Labs, Inc., acquired shares and warrants in a private placement transaction.

Stakeholder Impact

• Shareholders: The transaction may be interpreted as a sign of confidence by the CEO, potentially influencing investor sentiment. The exercise of warrants in the future could dilute existing shareholdings if exercised.
• Employees: May view the CEO's investment as a positive indicator for the company's future.
• Creditors: No direct impact indicated.

Next Steps

• Public announcement of data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325.
• Public announcement of receptor occupancy and safety data for SL-325.
• Public announcement of the design of the planned Phase 2 clinical trial(s) for SL-325.
• Warrants become exercisable 30 days following the aforementioned public announcements.

Key Dates

Keywords

Shattuck Labs, STTK, Form 4, Insider Transaction, Private Placement, Common Stock, Warrants, CEO, Beneficial Ownership, Clinical Trial Data